hnRNPM guides an alternative splicing program in response to inhibition of the PI3K/AKT/mTOR pathway in Ewing sarcoma cells

Heterogeneous nuclear ribonucleoprotein M associates with mTORC2 and regulates muscle differentiation

(2017) Wei-Yen Chen et al.   Scientific Reports

Robust stratification of breast cancer subtypes using differential patterns of transcript isoform expression

(2017) Thomas P. Stricker et al.   PLoS Genetics

The PI3K/AKT Pathway as a Target for Cancer Treatment

(2016) Ingrid A. Mayer et al.   Annual Review of Medicine

Rbfox Proteins Regulate Splicing as Part of a Large Multiprotein Complex LASR

(2016) Andrey Damianov et al.   CELL

Alternative splicing and cell survival: from tissue homeostasis to disease

(2016) Maria Paola Paronetto et al.   CELL DEATH AND DIFFERENTIATION

Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases

(2016) Jing Ni et al.   NATURE MEDICINE

Therapeutic targeting of splicing in cancer

(2016) Stanley Chun-Wei Lee et al.   NATURE MEDICINE

mTORC1 and mTORC2 in cancer and the tumor microenvironment

(2016) L C Kim et al.   ONCOGENE

Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review

(2015) Zebo Huang et al.   Future Oncology

Genotoxic stress inhibits Ewing sarcoma cell growth by modulating alternative pre-mRNA processing of the RNA helicase DHX9

(2015) Marco Fidaleo et al.   Oncotarget

Combined therapy with RAD001 e BEZ235 overcomes resistance of PET immortalized cell lines to mTOR inhibition

(2015) Ilaria Passacantilli et al.   Oncotarget

Cell type-restricted activity of hnRNPM promotes breast cancer metastasis via regulating alternative splicing

(2014) Y. Xu et al.   GENES & DEVELOPMENT

Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia

(2014) N Sandhöfer et al.   LEUKEMIA

MLN0128, an ATP-Competitive mTOR Kinase Inhibitor with Potent In Vitro and In Vivo Antitumor Activity, as Potential Therapy for Bone and Soft-Tissue Sarcoma

(2014) E. K. Slotkin et al.   MOLECULAR CANCER THERAPEUTICS

Both Decreased and Increased SRPK1 Levels Promote Cancer by Interfering with PHLPP-Mediated Dephosphorylation of Akt

(2014) Pingping Wang et al.   MOLECULAR CELL

PI3K and cancer: lessons, challenges and opportunities

(2014) David A. Fruman et al.   NATURE REVIEWS DRUG DISCOVERY

Context-dependent control of alternative splicing by RNA-binding proteins

(2014) Xiang-Dong Fu et al.   NATURE REVIEWS GENETICS

A day in the life of the spliceosome

(2014) A. Gregory Matera et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

The ets transcription factor Fli-1 in development, cancer and disease

(2014) Y Li et al.   ONCOGENE

Regulation of FAS Exon Definition and Apoptosis by the Ewing Sarcoma Protein

(2014) Maria Paola Paronetto et al.   Cell Reports

NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate

(2013) Bérengère Gobin et al.   CANCER LETTERS

mTOR in aging, metabolism, and cancer

(2013) Marion Cornu et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

The Akt-SRPK-SR Axis Constitutes a Major Pathway in Transducing EGF Signaling to Regulate Alternative Splicing in the Nucleus

(2012) Zhihong Zhou et al.   MOLECULAR CELL

The spliceosome as a target of novel antitumour drugs

(2012) Sophie Bonnal et al.   NATURE REVIEWS DRUG DISCOVERY

Integrative Genome-wide Analysis Reveals Cooperative Regulation of Alternative Splicing by hnRNP Proteins

(2012) Stephanie C. Huelga et al.   Cell Reports

The Ewing Sarcoma Protein Regulates DNA Damage-Induced Alternative Splicing

(2011) Maria Paola Paronetto et al.   MOLECULAR CELL

Understanding splicing regulation through RNA splicing maps

(2011) Joshua T. Witten et al.   TRENDS IN GENETICS

NVP-BEZ235 as a New Therapeutic Option for Sarcomas

(2010) M. C. Manara et al.   CLINICAL CANCER RESEARCH

Targeting insulin-like growth factor 1 receptor in sarcomas

(2010) Katia Scotlandi et al.   CURRENT OPINION IN ONCOLOGY

Cotranscriptional exon skipping in the genotoxic stress response

(2010) Martin Dutertre et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Global regulation of alternative splicing during myogenic differentiation

(2010) Christopher S. Bland et al.   NUCLEIC ACIDS RESEARCH

Recent advances in the molecular pathogenesis of Ewing's sarcoma

(2010) E C Toomey et al.   ONCOGENE

The Spliceosome: Design Principles of a Dynamic RNP Machine

(2009) Markus C. Wahl et al.   CELL

Co-transcriptional splicing of constitutive and alternative exons

(2009) A. Pandya-Jones et al.   RNA

Childhood and adolescent cancer survival in the US by race and ethnicity for the diagnostic period 1975-1999

(2008) Amy M. Linabery et al.   CANCER

Multiple Alternative Splicing Markers for Ovarian Cancer

(2008) R. Klinck et al.   CANCER RESEARCH

Identification of Alternative Splicing Markers for Breast Cancer

(2008) J. P. Venables et al.   CANCER RESEARCH

Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies

(2008) Monica M. Mita et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

(2008) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS